Lucentis improves myopic choroidal neovascularization

ZURICH (Reuters) - Switzerland's Novartis said on Wednesday new data for Lucentis demonstrated its benefits in treating myopic choroidal neovascularization secondary to pathological myopia, which Novartis will seek approval for.

Full Story →